跳至主要内容
临床试验/ACTRN12621001726842
ACTRN12621001726842已完成未知

Palmitoylethanolamide (PEA) as an adjuvant to resistance training – can PEA augment muscle growth, power and strength in young, active, healthy adults when combined with resistance training?

Deakin University0 个研究点目标入组 50 人开始时间: 2021年12月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 35 Years(—)
性别
All

入选标准

  • Key inclusion criteria: 1) Male or female 18-35 years of age and have had double COVID-19 vaccination done 2) recreationally active and non-resistance trained 3) have maintained a stable weight for the past 2 months (no more than ±2 kgs of weight change) 4) currently not consuming any other prescribed or non-prescribed analgesics

排除标准

  • Participants will be excluded based on the following: 1) they self-report as having had a musculoskeletal injury in the past 6 months 2) participation in structured resistance training in the past 6 months 3) allergies to any of the contents of the Levagen+ supplement 4)BMI <18.5 or BMI >28 5) currently participating in a weight loss program or special diet (e.g. Low carbohydrate, ketogenic, vegan etc) 6) current smokers 7) acute or terminal illness, functional impairment that would limit inclusion in the trial 8) use of sports supplements or pain medication in the last month 9) current chronic disease including cancer, diabetes, cardiovascular disease, chronic liver disease, and gastrointestinal disorders that affects nutrient absorption 10) cognitive impairment or inability to commit to the study and its requirements.

研究者

相似试验